Clinical Trials
Your safety and well-being are important to us. Please read the following information in its entirety before continuing on this page:
- Ensure you fully understand the details of the clinical trial before agreeing to participate. Carefully read and ask questions about the informed consent document provided by the research team. Take your time to review the potential risks, benefits, and procedures involved.
- If you are under the age of 18, obtain the consent of a parent or legal guardian before participating.
- Before enrolling, please confirm that you meet all eligibility criteria outlined in the trial protocol. Inform the research team of any pre-existing conditions or medications you are currently taking.
- Understand the measures in place to protect your privacy and the confidentiality of your medical information.
Acute Abdomen in Adults- a Prospective Study on Emergency Department Admissions
This is a non-randomized, prospective, population-based, single-center study designed to evaluate conditions resulting emergency admission in patients with abdominal pain. Furthermore, we are interested in how many patients are discharged with “non-specific abdominal pain” but later readmitted and diagnosed with a specific diagnosis.
Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet
The main aim is to see how TAK-062 works to reduce celiac-related symptoms and improve small intestinal damage due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.
Study to Assess the Safety of TPM502 in Adults With Celiac Disease
The goal of this clinical trial is to learn about the safety and the pharmacodynamic (PD) effects of TPM502 in adults with celiac disease. The main questions it aims to answer are:
- if TPM502 is safe and well tolerated.
- – if TPM502 can induce modifications in parameters indicating that it may induce tolerance to gluten.
Participants will:
- undergo 1-day gluten challenge during screening and after administration of TPM502 or placebo.
- receive 2 infusions of TPM502 or placebo, 2 weeks apart
Bio-markers of not-Celiac Wheat Sensitivity
The aim of the investigators’ study is to evaluate biochemical, immunological and histological characteristics of patients affected with the so-called “gluten (or wheat) sensitivity” who suffers from irritable bowel syndrome (IBS)-like symptoms. As it is not known what component of the cereals causes the symptoms in so called “gluten-sensitive” patients, the investigators prefer to speak of “not-celiac wheat sensitivity” (NCWS). NCWS patients may be defined as ones, neither celiac or allergic to wheat, who develop symptoms following wheat consumption, that improved on wheat/gluten free diet (GFD)